MAGEA4-directed TCR-T cell therapy( JW Therapeutics)

N/A

Report date: 2024/04/02 17:34:11

Base Information

Drug NameMAGEA4-directed TCR-T cell therapy( JW Therapeutics)
Drug Alias NameAutologous Humanized MAGE-A4-directed T Cell Receptor Engineered T Cell therapy(Peking University)autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell therapy(Peking University)TCR-MAGE-A4 T-Cells therapy(Peking University)MAGE-A4-directed T cell receptor-engineered T Cells therapy(Peking University)JWTCR001 +[6] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsMelanoma-associated antigen 4 modulators
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Ming Ju Biotechnology Co LtdJw Therapeutics (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJw Therapeutics (Shanghai) Co LtdPeking University2seventy Bio Inc +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A